about
Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adultsAcute treatment of migraine. Breaking the paradigm of monotherapyDifferences of anti-nociceptive mechanisms of migraine drugs on the trigeminal pain processing during and outside acute migraine attacksEFNS guideline on the drug treatment of migraine - report of an EFNS task forceEFNS guideline on the drug treatment of migraine--revised report of an EFNS task forceThe premonitory symptoms (prodrome): a tertiary care study of 893 migraineursTransient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptanUse and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data.Providing relief from headache pain. Current options for acute and prophylactic therapy.Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.Acute Migraine Treatment in Adults.Preclinical neuropharmacology of naratriptan.Visual Snow: a Potential Cortical Hyperexcitability Syndrome.Preventing disturbing migraine aura with lamotrigine: an open study.Efficacy of frovatriptan as compared to other triptans in migraine with aura.Late-life migraine accompaniments: A narrative review.Migraine, allodynia, sensitisation and all of that ...Review of clinical trials using early acute intervention with oral triptans for migraine management.Migraine: a review and future directions for treatment.Over-the-counter triptans for migraine : what are the implications?Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine.Insights from experimental studies into allodynia and its treatment.Management of sporadic and familial hemiplegic migraine.Transcranial magnetic stimulation for migraine: a safety review.Migraine with aura: conventional and non-conventional treatments.Pharmacological synergy: the next frontier on therapeutic advancement for migraine.The premonitory phase of migraine and migraine management.Migrainous infarction: aspects on risk factors and therapy.Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice.The typical duration of migraine aura: a systematic review.The visual system in migraine: from the bench side to the office.Treatment of migraine with rizatriptan: when to take the medication.Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat.Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.On the methodology of drug trials in migraine with aura.Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.Management of vestibular migraine.Vasodilator agents and supracollicular transection fail to inhibit cortical spreading depression in the cat.CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine.Triptans: where things stand.
P2860
Q24203684-8115C7B9-7978-454E-B099-5AB1D5D17248Q24796736-CE81E70F-92E9-4A1E-AB8A-A133AD2101EDQ28209205-FBBEAECD-2708-4AC2-BC13-579916EFA9FDQ28219436-60ACEB25-5463-4B6D-B38D-BE071FE19115Q28256451-786B85B2-3DCF-48E2-8E85-60939F8E223CQ28284647-1C8F5863-2C19-42A5-B6FA-AD1D9CF334F1Q28376502-7B694835-AA6E-4C32-9C6F-5FFDA6B75679Q30584718-0299EAB1-67B3-4FC9-B4FE-4BFB5FB4CEC8Q34044773-A135B132-89E0-4ED5-9408-BFF2AEF61584Q34127399-E1C97358-6FC1-40E1-862C-4858B6F84B6AQ34471863-58DADE17-0FE3-485E-ACEC-11C8E8F51114Q34481166-C89DB477-5A89-43B1-B5B7-E224A6DC7C8CQ34554230-CD1BE9BF-559F-427B-8336-76DA7F7C1FC0Q34650041-2DE6533C-B904-4FDC-8BB6-D844FBB3B0FCQ35418862-7CA4929F-AD67-4A8D-AF0E-978F2270E653Q35518633-3E1274D0-D68F-44B6-8777-74F519E6811BQ36141468-338BF2B7-2A61-42CC-ADC6-297967B3E603Q36521901-F25E2C92-9C48-42E6-9A00-D09AB161DAF3Q36546603-4244786A-7F74-4386-9272-363AAC4C303EQ36967184-A9B5C619-ACD5-48B2-BE68-FFD2FF4AF4ADQ37254528-DF0797E4-2812-486F-AA2F-B85F50575059Q37263431-E04D0CA8-D06F-4AF8-942F-DDB94A046CE2Q37699418-3DF5555B-DB78-4D9E-8022-FCF6370B481BQ37765637-7D0B178D-91C6-47AC-9927-E959F4E57E2DQ37870798-E904D548-E6F5-41A1-9AF9-9F34D1DDFB99Q37973436-39A2B130-A45E-42A5-B4DD-92714CE43F60Q37984286-541F5D3D-5C12-4850-8EB9-159763C7E0E6Q38004939-B442B3E2-760D-44E8-B260-5C6B4A5E7878Q38046616-62217D70-D6A5-4331-8973-95B428638BEFQ38087899-BDDFA2AC-E5EF-4783-B014-F25B28DAAB0EQ38347056-11FF20B5-345A-45B9-A913-D890C9E22364Q39407215-5EA483D6-AD26-4660-B193-CC8907BC21ACQ39443442-33D51230-0BD6-40E2-A4EE-B9F5822189ACQ39471681-974ACB8A-4031-4816-8C11-08DDADEA6175Q39847033-35F961AB-269A-4F4A-AC37-B3A496CA1683Q41661654-863E62C8-C1D2-4B26-BFBD-742A0BCAFF10Q41765630-07217EE6-4D42-4D23-A70B-67B5800F69E5Q42607926-13B93A4F-029C-478E-9C8D-ACB3AEC1376AQ42854065-88FEFBE5-E759-4F6E-97EF-ECA919090FFAQ42906989-31801A11-6C6F-48F4-9533-C3C8460B35F3
P2860
description
im September 1994 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 September 1994
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 1994
@uk
name
Subcutaneous sumatriptan during the migraine aura
@en
Subcutaneous sumatriptan during the migraine aura
@nl
type
label
Subcutaneous sumatriptan during the migraine aura
@en
Subcutaneous sumatriptan during the migraine aura
@nl
prefLabel
Subcutaneous sumatriptan during the migraine aura
@en
Subcutaneous sumatriptan during the migraine aura
@nl
P2093
P356
P1433
P1476
Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group
@en
P2093
A J Pilgrim
F B Ensink
N E Gilhus
P304
P356
10.1212/WNL.44.9.1587
P407
P50
P577
1994-09-01T00:00:00Z